Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.

Natalia V MitiushkinaAlexandr A RomankoElena V PreobrazhenskayaVladislav I TiurinTatiana I ErmachenkovaAlexandr S MartianovRimma S MulkidjanTatiana N SokolovaMaksim M KholmatovIlya V BizinAlexandr O IvantsovOlga S YatsukOlga A ZaitsevaAglaya G IyevlevaEkatherina Sh KuliginaEvgeny N Imyanitov

Published in: Cancer medicine (2022)

Comprehensive ALK analysis can be performed by the test for 5'-/3'-end unbalanced expression with minimal risk of missing an ALK rearrangement. In contrast, the use of the test for 5'-/3'-end unbalanced expression for the detection of ROS1 fusions is complicated; hence, the utilization of variant-specific PCR assays for ROS1 testing is preferable.

Keyphrases

poor prognosis
cell death
dna damage
binding protein
advanced non small cell lung cancer
reactive oxygen species
computed tomography